Director, Global Compound Market Access Leader, Hematology Oncology Early Pipeline & NBD

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com

Job Function:

Market Access

Job Sub Function:

Health Economics Market Access

Job Category:

People Leader

All Job Posting Locations:

Horsham, Pennsylvania, United States of America, Raritan, New Jersey, United States of America

Job Description:

The Global Commercial Strategy Organization, a group within Johnson & Johnson Innovative Medicine Global Services and a member of Johnson & Johnson's family of companies, is recruiting for a Global Compound Market Access Leader. This position will be based in Raritan, NJ or Horsham, PA.

The Global Compound Market Access Leader (CMAL), Hematology Oncology Early Pipeline & NBD reporting to the Global Senior CMAL, Oncology Early Pipeline & NBD, has the key leadership role of developing and shaping the Clinical Development Plan (CDP), trial designs and Market Access strategy for the assigned assets in the early Hematology Oncology portfolio. The CMAL provides strategic market access leadership across assets, expertly representing market access within Compound Development Team and other global strategy teams, building strong relationships and effective collaboration within the matrix. In doing so, the CMAL will shape key strategic decisions through input/contributions to Clinical Development and Integrated Evidence Generation Plans to ensure that strategic plans fully meet the needs of market access in key countries. The CMAL takes a lead in development of brand value propositions and collaborates through the (Extended) Market Access Team to support timely, optimal input into CDPs & clinical trial designs to enable reimbursement in a highly challenging environment across diverse regions with complex and differing needs. The CMAL must understand the needs of markets and develop appropriate solutions.

Key Responsibilities:

· Supporting assets and indications ahead of full investment in dedicated product teams, including assets prior to transition to full development, or additional indications outside current disease area strategy team remits.

· Evaluation and strategic input into New Business Development opportunities to maximize deal value and support decision making.

· Responsible for ensuring that clinical development programs fully capture the value of innovative products to payers, physicians and patients. This includes strategic advice to teams on patient populations, trial design, selection of relevant endpoints as well as ensuring quality implementation of study protocols, case report forms, monitoring protocols, statistical analyses plans, etc.

· Direct the work of cross functional teams, which include the core functions within Global Market Access (i.e Health Economics, Patient Reported Outcomes [PRO], Access Policy, Pricing, Real World Evidence & Analytics) to deliver the global market access strategy for each brand/asset.

· Design, develop and implement an integrated approach to all aspects of the payer value proposition from early development through to appointment of a dedicated product team for a complex portfolio of compounds and indications.

· Responsible for the early strategic planning and implementation of the payer value generation and access strategies.

· Serve as the leading resource on access strategies and is an active member of the global clinical and commercial product teams, as well as the disease area strategy groups.

· Responsible for integrating pricing, payer research, health economic and epidemiology information to develop the optimal value strategy.

· Develop an integrated access strategy that reflects macro (health care reform, quality metrics, technology assessment) and disease specific (clinical profile, market segmentation, disease staging and clinical pathway) factors as well as the complexity of a companion diagnostic.

· Responsible for educating the commercial and R&D teams on key access trends and opportunities to shape their evolution.

· Provide leadership to the Clinical Development Team (CDT) in terms of market access data needs related to the clinical development plan; represent the access needs of the regions as a subject matter expert and advocate for the data